江蘇鵬鷂藥業(yè)有限公司
江蘇鵬鷂藥業(yè)有限公司
Main Products:Azithromycin Dispersible Tablets, Gliclazide Tablets (II), Chlorphenamine Maleate Tablets,
View moreAbout Us
Contact Supplier
Hot Products
+ more
Azithromycin Dispersible Tablets
Health & Medical/Pharmaceuticals & Raw Materials/Chemical APIsNegotiable
Send Inquiry
Gliclazide Tablets (II)
Health & Medical/Pharmaceuticals & Raw Materials/Chemical APIsNegotiable
Send Inquiry
Chlorphenamine Maleate Tablets
Health & Medical/Pharmaceuticals & Raw Materials/Chemical APIsNegotiable
Send Inquiry
Ningxinbao Capsule
Health & Medical/Pharmaceuticals & Raw Materials/Chemical APIsNegotiable
Send Inquiry
Pengyao Brand Danshen, Eucommia, and Epimedium Capsules
Health & Medical/Pharmaceuticals & Raw Materials/Chemical APIsNegotiable
Send Inquiry
Fursultiamine Tablets
Health & Medical/Pharmaceuticals & Raw Materials/Chemical APIsNegotiable
Send Inquiry
Pengyao Brand Ganoderma Lucidum Spore Powder and Ginkgo Biloba Extract Capsules
Chemicals/Pharmaceutical Raw Materials/Amino Acids & DerivativesNegotiable
Send Inquiry
Calamine Lotion (Boxed)
Chemicals/Chemical Intermediates/Intermediate CompoundsNegotiable
Send Inquiry
Compound Glycyrrhizin Tablets
Health & Medical/Pharmaceuticals & Raw Materials/Chemical APIsNegotiable
Send Inquiry
Acyclovir Tablets
Health & Medical/Pharmaceuticals & Raw Materials/Chemical APIsNegotiable
Send InquiryCompany Profile
+ more
Jiangsu Pengyao Pharmaceutical Co., Ltd. is a leading comprehensive professional preparation enterprise in Yixing City, with a registered capital of 1.62 million US dollars. It currently employs over 300 staff, including more than 100 professionals with various titles, 2 master's degree holders, and 1 doctoral degree holder. The company boasts a dynamic and proactive professional management team.
The product portfolio encompasses over 10 series, more than 10 dosage forms, and over 200 specifications, covering areas such as digestive system drugs, circulatory system drugs, and antipyretic analgesics, integrating both traditional Chinese and Western medicines. Nearly 90 products are listed in the National Essential Drug List. Main dosage forms include tablets, capsules, solutions, large-volume injections, small-volume injections, pills, suspensions, dropping pills, soft capsules, and active pharmaceutical ingredients. The company has developed Yiganling Dispersible Tablets and Azithromycin Dispersible Tablets, which are highly popular in numerous provinces, municipalities, and regions including Beijing, Tianjin, Jiangsu, Hunan, Hubei, Shandong, Anhui, and Shaanxi, establishing a strong reputation and customer base within the industry. Building on existing product technology, the company will focus on liver protection products as its primary development direction, aiming to become a major player in this field.
The company possesses robust technical capabilities, state-of-the-art equipment, advanced technology, and standardized management. With extensive production experience and a strict quality management control system, it adheres to the principle of "ensuring product quality and safeguarding human health." The company consistently upholds the philosophy of "prioritizing quality, managing efficiently, driving innovation, surviving through quality, and expanding markets with diverse products."
To achieve greater development goals, the company is investing in the construction of a modern factory covering approximately 180 acres in the Yixing Environmental Protection Technology Industrial Park. Utilizing superior production equipment and complying with national standards such as the new "Good Manufacturing Practice for Drugs," "Clean Room Facility Standards," "Health Pre-evaluation Standards for Industrial Construction Projects," and "Fire Protection Design Standards for Buildings," the factory will feature well-organized production, storage, administrative, and living areas with clear functional divisions and separate flows for personnel and materials. The facility will be a garden-style modern factory meeting the 2010 GMP standards.
The expansion is divided into two phases. The first phase involves an investment of 228 million RMB, covering the construction of workshops for all existing dosage forms, dropping pills, soft capsules, and health food products. Currently, the factory buildings and equipment are largely in place, with full completion and operation expected by December 2011. The second phase, with an investment of 250 million RMB, will include two lyophilized powder injection production lines and a multifunctional research institute, focusing on biopharmaceuticals and traditional Chinese medicine as future development directions.
By relocating and expanding existing workshops, the company has enhanced its production capacity and added new dosage forms, strengthening its competitive edge. Post-expansion annual production outputs will include: 5 billion tablets, 500 million capsules, 40 million bottles (bags) of infusions, 200 million small-volume injections, 50 million bags of traditional Chinese medicine pills, 5 million bottles of external preparations, 50 tons of active pharmaceutical ingredients, 200 million soft capsules, 5,000 kg of dropping pills, and 100 million bottles of lyophilized powder injections, with an estimated output value of 500 million to 1 billion RMB.
For many years, the company has adhered to the corporate philosophy of "quality first, pursuing human health," embodying the spirit of "upholding virtue and striving for excellence." It follows the operational宗旨 of "creating brands with quality, surviving with integrity, seeking efficiency through management, and developing with technology." The company has been consistently recognized as a high-tech enterprise, a Jiangsu Province Contract-Honoring and Credit-Worthy Enterprise, and a Jiangsu Province AAA Credit Enterprise.
